On Feb 4, 2023, Dr. Jason Shaoyun Xiang, founder and CEO of Polymed Biopharmaceutical, gave a speech on Protac at the famous Boston Seal Club, and introduced the clinical candidate compound HPB-143 discovered by the company. According to Dr Xiang, when working on the drug discovery for an important target Polymed not only established a complete protein degradation drug discovery platform, but also solved the oral bioavailability issue of PROTAC compounds the entire field often faces. The presentation was enthusiastically received and followed by very active discussions. Dr. Wang, Vice President of the company's Biology Department, and Dr. Lu, Senior Vice President of the Technology Department, also participated in the event.